posteditor

B Study objective is to demonstrate that treatment with vapendavir can mitigate or prevent worsening of respiratory symptoms caused by rhinovirus, which often lead to… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Organic revenue growth1 of 4% with growth in all operating segments Operating income2 grew 10%, resulting in further margin expansion to 10.1% FME25+ transformation program related… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution Recognition highlights proactive alignment with evolving expectations from global stakeholders… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B NEW YORK, May 5, 2026 /PRNewswire/ — Statement from Samantha Rose, Executive Vice President, Head of Integrated Investment and Programmatic, Horizon Media: As we enter… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Free Program Conveniently Delivers Tips to Caregivers’ Smartphones ROCKVILLE, Md., May 5, 2026 /PRNewswire/ — Feeding challenges are among the most common—and stressful—issues that families… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B PITTSBURGH, May 5, 2026 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) today announced that on May 4, 2026, its Board of Directors declared a quarterly dividend… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B FINDLAY, Ohio, May 5, 2026 /PRNewswire/ —  Delivering mid-single digit growth strategy through expansions of Permian sour gas treating capacity, natural gas and NGL… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B FINDLAY, Ohio, May 5, 2026 /PRNewswire/ — First-quarter net income attributable to MPC of $511 million, or $1.73 per diluted share, adjusted net income… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease… Login to continue reading Login Sign up for complimentary access Sign Up Now Close

B Recognized as one of just five Leaders out of 18 evaluated vendors in the first-ever Gartner® evaluation of threat intelligence market, Group-IB’s adversary-centric, predictive… Login to continue reading Login Sign up for complimentary access Sign Up Now Close